Cardiac Ablation Devices Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update
Cardiac Ablation Devices Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update
Summary
GlobalData's Medical Devices sector report, “Cardiac Ablation Devices Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update provides comprehensive information about the Cardiac Ablation Devices pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Cardiac Ablation Devices are devices that use radiofrequency energy to destroy cardiac tissues which propagate incorrect electrical signals to cause an abnormal heart rhythm.
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
Extensive coverage of the Cardiac Ablation Devices under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of Cardiac Ablation Devices and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment / industry
Reasons to Buy
The report enables you to -
Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
Identify and understand important and diverse types of Cardiac Ablation Devices under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product’s current stage of development, territory and estimated launch date
1 About GlobalData
2 Table of Contents
2.1 List of Tables
2.2 List of Figures
3 Introduction
3.1 Cardiac Ablation Devices Overview
4 Products under Development
4.1 Cardiac Ablation Devices - Pipeline Products by Stage of Development
4.2 Cardiac Ablation Devices - Pipeline Products by Territory
4.3 Cardiac Ablation Devices - Pipeline Products by Regulatory Path
4.4 Cardiac Ablation Devices - Pipeline Products by Estimated Approval Date
7.1 Mar 14, 2024: Methodist Le Bonheur Healthcare first in Tennessee to offer Paradigm-Shifting Technology for AFib patients
7.2 Mar 12, 2024: Medtronic To Present At Barclays Global Healthcare Conference
7.3 Mar 07, 2024: Overlake First in Pacific Northwest to Treat Atrial Fibrillation With New FDA-Approved Pulsed Field Ablation
7.4 Mar 01, 2024: Biosense Webster secures CE mark for Varipulse PFA system
7.5 Mar 01, 2024: SMH Physicians Using Break-Through Device to Treat Patients with AFib
7.6 Mar 01, 2024: WRH Electrophysiology Performs Innovative Procedure
7.7 Feb 28, 2024: Catheter Precision Announces the First Use of VIVO With a Pediatric Patient in Turkey
7.8 Feb 28, 2024: Boston Scientific Raises $2.2B to Support Purchase of California Medical Device Company
7.9 Feb 23, 2024: Medical Tech Leader, Boston Scientific (BSX), Announces Notes Offering
7.1 Feb 19, 2024: Boston Scientific Appoints Madan Krishnan to Lead India Subcontinent
7.11 Feb 14, 2024: Farapulse Obtains Pre-Market Approval (PMA) for FARAPULSE Pulsed Field Ablation (PFA) System
7.12 Feb 14, 2024: Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX nsPFA 360° Cardiac Catheter First-in-Human Feasibility Study
7.13 Feb 08, 2024: Biosense Webster Supports Collaborative Studies That Aim to Expand Knowledge in Pulsed Field Ablation
7.14 Feb 06, 2024: J&J unveils Varipulse data at AF Symposium
7.15 Feb 02, 2024: Biosense Webster Presents Late-Breaking Data from inspIRE and admIRE Clinical Trials at AF Symposium
7.16 Jan 31, 2024: Boston Scientific Receives FDA Approval for FARAPULSE Pulsed Field Ablation System
7.17 Jan 31, 2024: Pulse Biosciences Announces Preliminary Findings from Its CellFX nsPFA 360 Cardiac Catheter First-in-Human Feasibility Study to Be Featured in Podium Presentation at the AF Symposium
7.18 Jan 31, 2024: Boston Scientific Announces Results for Fourth Quarter and Full Year 2023
7.19 Jan 18, 2024: Abbott Announces First Global Procedures in a Clinical Trial of its Volt Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms
7.2 Jan 09, 2024: Biosense Webster Announces Regulatory Approval of VARIPULSE Pulsed Field Ablation (PFA) Platform in Japan
7.21 Jan 05, 2024: Boston Scientific Announces Conference Call Discussing Fourth Quarter 2023 Results
7.22 Jan 05, 2024: AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 Guidance
7.23 Dec 28, 2023: Boston Scientific Initiates Avant Guard Clinical Trial to Evaluate Farapulse Pulsed Field Ablation System as First-Line Treatment for Persistent Atrial Fibrillation
7.24 Dec 21, 2023: Pulse Biosciences concludes procedures with cardiac catheter in study
7.25 Dec 14, 2023: Medtronic obtains US FDA approval for PulseSelect PFA system
7.26 Dec 13, 2023: Medtronic creates history with FDA approval of its novel PulseSelect Pulsed Field Ablation System to treat atrial fibrillation
7.27 Nov 21, 2023: Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode
7.28 Nov 20, 2023: Catheter Precision's (VTAK) First Successful VIVO Cases Completed in Croatia Sets Stage for Expansion into South-Eastern Europe
7.29 Oct 26, 2023: Boston Scientific Announces Results for Third Quarter 2023
7.3 Oct 10, 2023: Thermedical Awarded $3 Million NIH Grant to Study Promising Treatment for Ventricular Tachycardia, a Leading Cause of Sudden Cardiac Death
7.31 Oct 08, 2023: Late-Breaking Data Confirms Safety of Axon Therapies' Innovative Heart Failure Procedure and Identifies Patients Most Likely to Benefit from SAVM Therapy
7.32 Oct 04, 2023: Stereotaxis Robotic Technology to be Featured during 7th Annual Meeting of the Society for Cardiac Robotic Navigation
7.33 Oct 04, 2023: Medtronic Names Paolo Di Vincenzo President of the Neuromodulation Business
7.34 Oct 02, 2023: Pulse Biosciences and Cardionxt to Collaborate on nsPFA First-In-Human Study
7.35 Sep 29, 2023: Pulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA™) Circumferential Catheter System to be Featured in a Presentation at the Global EP Summit
7.36 Sep 27, 2023: Pulse Biosciences’ First Study in a Surgical Application of Nanosecond Pulsed Field Ablation (nsPFA) Technology to be Featured in Two Poster Presentations at the American Thyroid Association Annual Meeting
7.37 Sep 19, 2023: Canadian First - Abbott's TactiFlex Ablation Catheter Used to Treat AFib
7.38 Sep 18, 2023: Biosense Webster Begins Evaluation of Large-tip Focal Pulsed Field Ablation Catheter in Omny-IRE Clinical Trial in Europe
7.39 Aug 27, 2023: ADVENT Study of the FARAPULSE Pulsed Field Ablation System Meets Primary Efficacy and Safety Endpoints
7.4 Aug 26, 2023: Medtronic Q2 2024 Earnings Estimates Increased by William Blair
7.41 Aug 09, 2023: FDA grants approval for Boston Scientific’s cryoablation system
7.42 Aug 08, 2023: Medtronic to Announce Financial Results for its First Quarter of Fiscal Year 2024
7.43 Jul 24, 2023: Ra Medical System’s Electrophysiology Division Has Increased Demand for Its Non-invasive Mapping System
7.44 Jul 19, 2023: Boston Scientific lays off 52 workers as it closes another Silicon Valley facility
7.45 May 31, 2023: Kardium announces first US procedures in PULSAR study of Globe Pulsed Field System
7.46 May 22, 2023: Abbott gets FDA nod for TactiFlex Ablation Catheter to treat AFib
7.47 May 20, 2023: Data at Heart Rhythm 2023 highlight key Boston Scientific therapies
7.48 May 19, 2023: Varian announces first participant treated in RADIATE-VT clinical trial of cardiac radioablation for patients with Refractory Ventricular Tachycardia
7.49 May 19, 2023: Biosense Webster presents new data from pulsed field ablation investigational studies at Heart Rhythm 2023
7.5 May 19, 2023: Medtronic PulseSelect Pulsed Field Ablation System results in low Atrial arrhythmia burden for AFib patients
7.51 May 18, 2023: Pulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA) technology to be featured in several presentations at The Heart Rhythm 2023 Annual Meeting
7.52 May 18, 2023: Pre-clinical Pulsed-Field Ablation (PFA) Using a Single-Shot Circular Linear Ablation Catheter for PV Isolation
7.53 May 11, 2023: Medtronic to announce financial results for its fourth quarter and full fiscal year 2023
7.54 May 03, 2023: Adagio Medical announces completion of enrollment in Cryocure-VT trial, maps the pathway to CE-Mark of vCLAS VT ablation catheter
7.55 Apr 17, 2023: Ra Medical electrophysiology division is participating in EHRA Congress
7.56 Apr 12, 2023: Medtronic has a layoff in California
8 Appendix
8.1 Methodology
8.2 About GlobalData
8.3 Contact Us
8.4 Disclaimer
2.1 List of Tables
Table 1: Cardiac Ablation Devices - Pipeline Products by Stage of Development
Table 2: Cardiac Ablation Devices - Pipeline Products by Territory
Table 9: Volt Pulsed Field Ablation System - Product Status
Table 10: Volt Pulsed Field Ablation System - Product Description
Table 11: Abbott Medical - Ongoing Clinical Trials Overview
Table 12: Volt Pulsed Field Ablation System - A Pre-market, Multi-centered Clinical Study to Evaluate the Safety and Effectiveness of Volt Pulsed Field Ablation System
Table 16: CircumBlator AF Catheter Ablation System - Product Status
Table 17: CircumBlator AF Catheter Ablation System - Product Description
Table 18: AccuPulse Medical Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 19: PFA Pulsed Electric Field Ablation System - Product Status
Table 20: PFA Pulsed Electric Field Ablation System - Product Description
Table 21: AccuPulse Medical Technology Co Ltd - Ongoing Clinical Trials Overview
Table 22: PFA Pulsed Electric Field Ablation System - Feasibility and Safety Evaluation of the Pulsed Electric Field Ablation System on Patients with Chronic Bronchitis
Table 49: Sphere9 Catheter - Study to Evaluate the Safety and Efficacy of Lattice Sphere Catheter to Reduce Complication Risk During Cardiac Ablation
Table 50: Affera Mapping and Ablation System - First-in-human Study Evaluating the Safety and Effectiveness of the SpherePVI Catheter and Affera System in Patients with Atrial Fibrillation
Table 51: Affera Mapping and Ablation System - The Affera Global Registry Is A Prospective, Global, Multi-center, Observational Post-Market Registry (PMR)
Table 52: Affera Mapping and Ablation System - Treatment of Persistent Atrial Fibrillation with the Sphere-9 Mapping and Ablation Catheter and the Affera Mapping and Ablation System
Table 53: SpherePVI - A Safety and Performance Assessment of the Affera SpherePVI Multi-Ablation System to Treat Paroxysmal Atrial Fibrillation
Table 54: SpherePVI - A Safety and Performance Assessment of the SpherePVI Catheter and the Affera Mapping and Ablation System to Treat Paroxysmal Atrial Fibrillation
Table 55: SpherePVI - First-in-human Study Evaluating the Safety and Effectiveness of the SpherePVI Catheter and Affera System in Patients with Atrial Fibrillation
Table 68: Coherent Sine-Burst Electroporation Ablation System - Product Status
Table 69: Coherent Sine-Burst Electroporation Ablation System - Product Description
Table 70: Non-Thermal Cardiac Ablation System - Product Status
Table 71: Non-Thermal Cardiac Ablation System - Product Description
Table 72: Arga Medtech SA - Ongoing Clinical Trials Overview
Table 73: Coherent Sine-Burst Electroporation Ablation System - An IDE Study Coherent Sine-Burst Pulsed Field Ablation (PFA) System in Treatment of Atrial Fibrillation
Table 83: AtriCure Bipolar System - Combined Endoscopic Epicardial and Percutaneous Endocardial Ablation Versus Repeated Catheter Ablation in Persistent and Longstanding Persistent Atrial Fibrillation
Table 88: Satera Ablation System - Endovascular Ablation of the Right Greater Splanchnic Nerve in Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF: Feasibility Study: Randomized Controlled Feasibility Trial - Rebalance-HF Study
Table 89: Baylis Medical Company Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 90: Cardiac Ablation Mitigating Device - Product Status
Table 100: VARIPULSE Catheter - Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation with the BWI IRE Ablation System (AdmIRE)
Table 101: VARIPULSE Catheter - Versatility of a Circular Multielectrode Catheter in the Individualized Recognition & Treatment of Atrial Fibrillation and Related Arrhythmias Using Pulsed Field Energy
Table 102: Omnypulse Bi-Directional Catheter - Safety and Effectiveness Evaluation of the OMNYPULSE Catheter With the TRUPULSE Generator for Treatment of Paroxysmal Atrial Fibrillation (PAF)
Table 132: Field Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 6
Table 133: FieldForce Ablation System - Product Status 6
Table 134: FieldForce Ablation System - Product Description 6
Table 135: Field Medical Inc - Ongoing Clinical Trials Overview 7
Table 136: FieldForce Ablation System - A Pre-Market, First-In-Human, Pilot, Interventional, Clinical Investigation to Evaluate Safety and Feasibility of the FieldForce™ Ablation System in Symptomatic Patients With Ventricular Arrhythmia 7
Table 141: Centauri System - Study Evaluating the Safety and Efficacy of the Centauri system (ECLIPSE-AF)
Table 142: Centauri System - Study Evaluating the Safety and Efficacy of the Centauri System in Patients with Persistent Atrial Fibrillation: SPACE-AF
Table 143: Hadassah Medical Center Pipeline Products & Ongoing Clinical Trials Overview
Table 144: Qualiblate - Product Status
Table 145: Qualiblate - Product Description
Table 146: Hangzhou Nuocheng Medical Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 147: Liwen RF Ablation System - Product Status
Table 148: Liwen RF Ablation System - Product Description
Table 149: Hangzhou Nuocheng Medical Technology Co Ltd - Ongoing Clinical Trials Overview
Table 150: Liwen RF Ablation System - Confirmatory Clinical Study of Liwen RF Ablation System
Table 151: Hangzhou Nuomao Medical Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 152: CardioPulse Field Ablation System - Product Status
Table 153: CardioPulse Field Ablation System - Product Description
Table 154: Hangzhou Nuomao Medical Technology Co Ltd - Ongoing Clinical Trials Overview
Table 155: CardioPulse Field Ablation System - An Exploratory Study of Focal Pulse Ablation System in the Treatment of Typical Atrial Flutter
Table 156: CardioPulse Field Ablation System - First in Man Study to Evaluate Safety and Efficacy of Left Atrial Appendage Pulsed Field Ablation Occluder for Simultaneous Pulsed Field Ablation and Mechanical Closure of the Left Atrial Appendage in Patients With Nonvalvular Atrial Fibrillation
Table 157: CardioPulse Field Ablation System - The Effectiveness and Safety of CardioPulse Pulse Ablation System in the Treatment of Paroxysmal Atrial Fibrillation